OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Forster on Recent Data With Lurbinectedin in SCLC

October 8th 2018

Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses data of lurbinectedin plus doxorubicin as a second-line therapy for patients with small cell lung cancer.

Dr. Shah Discusses Frontline Considerations for the Treatment of CML

October 5th 2018

Neil Shah, MD, PhD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco (UCSF) Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses frontline treatment considerations for patients with chronic myeloid leukemia.

Dr. Spigel Reflects on the PACIFIC Study in NSCLC

October 5th 2018

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non–small cell lung cancer.

Dr. Becerra Discusses Dosing Strategies in CRC

October 5th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses dosing strategies in the treatment of patients with colorectal cancer.

Cosmo Smith on the Difference Between Clinical Liquidity and Financial Liquidity

October 5th 2018

P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses the difference between clinical liquidity and financial liquidity.

Dr. Whitman on the Partnership Between Atlantic Health System, TGen and Origin

October 5th 2018

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses the partnership between Atlantic Health System, Translational Genomics Research Institute (TGen), and Origin Commercial Ventures.

Dr. Patterson on Off-Target Effects With TKIs in Pediatric CML

October 5th 2018

Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses the off-target effects with tyrosine kinase inhibitors (TKIs) in pediatric patients with chronic myeloid leukemia (CML).

Dr. Powell on the Future of Immunotherapy in Ovarian Cancer

October 5th 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses the future of immunotherapy in ovarian cancer.

Dr. Choueiri Discusses the CANTATA Trial in RCC

October 5th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CANTATA trial in renal cell carcinoma.

Dr. Sharma Discusses Immunotherapy in Prostate Cancer

October 5th 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immunotherapy in prostate cancer.

Dr. Oxnard Discusses RET Fusions in NSCLC

October 4th 2018

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, Dana-Farber Cancer Institute, discusses RET fusions in non–small cell lung cancer.

Dr. Cohen on Immunotherapeutic Advances in Head and Neck Cancer

October 4th 2018

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapeutic advances in head and neck cancer.

Dr. Chien on Treatment Duration in HER2+ Breast Cancer

October 4th 2018

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment duration in HER2-positive breast cancer.

Dr. Naidoo on the Mechanisms Behind Immune-Related Adverse Events in Lung Cancer

October 4th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses the mechanisms behind immune-related adverse events (irAEs) in lung cancer.

Dr. Yacoub on Pegylated Interferon Treatment for PV

October 4th 2018

Abdulraheem Yacoub, MD, associate professor of medicine, University of Kansas Medical Center, discusses the potential of pegylated interferon treatment in patients with polycythemia vera.

Dr. Upadhyaya on the Design of the SJYC07 Trial in Pediatric Patients With Ependymoma

October 4th 2018

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses the design of the 10-year-long SJYC07 trial.

Dr. Tewari on the Trial Design With Cemiplimab in Cervical Cancer

October 4th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the trial design with cemiplimab (Libtayo) in recurrent or metastatic cervical cancer.

Dr. Green on Early Relapse in Multiple Myeloma

October 4th 2018

Michael Green, MD, Northern California Oncologist, discusses early relapse in multiple myeloma.

Dr. Rule on Watching and Waiting Approach For MCL Subset

October 3rd 2018

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the “watching and waiting” approach for a subset of patients with mantle cell lymphoma.

Dr. Allison Discusses the Future of Immunotherapy in Cancer Care

October 2nd 2018

James P. Allison, PhD, chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, and a recipient of the 2018 Nobel Prize in Physiology or Medicine, discusses the future of immunotherapy in the treatment of patients with cancer.